New York, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Duchenne Muscular Dystrophy Drugs Industry" - https://www.reportlinker.com/p06040995/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Duchenne Muscular Dystrophy Drugs Market to Reach $18.1 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Duchenne Muscular Dystrophy Drugs estimated at US$1.1 Billion in the year 2022, is projected to reach a revised size of US$18.1 Billion by 2030, growing at a CAGR of 42.5% over the analysis period 2022-2030. Exon Skipping, one of the segments analyzed in the report, is projected to record a 48.6% CAGR and reach US$12.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Steroid Therapy segment is readjusted to a revised 32% CAGR for the next 8-year period.
The U.S. Market is Estimated at $312.7 Million, While China is Forecast to Grow at 40% CAGR
The Duchenne Muscular Dystrophy Drugs market in the U.S. is estimated at US$312.7 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 40% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 39.3% and 35.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 28.5% CAGR.
Select Competitors (Total 46 Featured)
- Acceleron Pharma, Inc.
- Akashi Therapeutics, Inc.
- BioMarin Pharmaceutical, Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Janssen Pharmaceuticals, Inc.
- Lexicon Pharmaceuticals, Inc.
- Nippon Shokubai Co., Ltd.
- Nobelpharma Co., Ltd.
- Pfizer, Inc.
- PTC Therapeutics, Inc.
- Sarepta Therapeutics Inc.
- Taiho Pharmaceutical Co., Ltd.
Read the full report: https://www.reportlinker.com/p06040995/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Duchenne Muscular Dystrophy (DMD) Drugs Market To Exhibit
Strong Growth
Duchenne Muscular Dystrophy Drugs - Global Key Competitors
Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
Global Market Dynamics
Treatment Overview and Recent Developments
Steroids used for the Treatment of DMD
Translarna Exhibits Positive Result in Children with DMD
Clinical Trials Depict Emflaza Preserves Motor Function Better
than Corticosteroids
Trial Shows Golodirsen Increases Dystrophin Production in DMD
Patients
Casimersen and Golodirsen Exhibits Positive Results in
Sarepta’s ESSENCE study
EXONDYS 51® Drug Details
FDA Approves Corticosteroid Emflaza for Treating DMD Patients
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Pipeline Analysis
Drug Price Details: Exondys51
Sarepta’s DMD Gene Therapy Trial Update
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Duchenne Muscular Dystrophy Drugs by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2022 through 2030 and % CAGR
Table 2: World 8-Year Perspective for Duchenne Muscular
Dystrophy Drugs by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World Markets for Years 2023 & 2030
Table 3: World Recent Past, Current & Future Analysis for
Mutation Suppression by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR
Table 4: World 8-Year Perspective for Mutation Suppression by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2023 & 2030
Table 5: World Recent Past, Current & Future Analysis for Exon
Skipping by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2022 through
2030 and % CAGR
Table 6: World 8-Year Perspective for Exon Skipping by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2023 & 2030
Table 7: World Recent Past, Current & Future Analysis for Other
Segments by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2022 through
2030 and % CAGR
Table 8: World 8-Year Perspective for Other Segments by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2023 & 2030
Table 9: World Duchenne Muscular Dystrophy Drugs Market
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2030
Table 10: World Recent Past, Current & Future Analysis for
Steroid Therapy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR
Table 11: World 8-Year Perspective for Steroid Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2023 & 2030
III. MARKET ANALYSIS
UNITED STATES
Duchenne Muscular Dystrophy Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in the United States
for 2023 (E)
Table 12: USA Recent Past, Current & Future Analysis for
Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping,
Steroid Therapy, Mutation Suppression and Other Segments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 13: USA 8-Year Perspective for Duchenne Muscular
Dystrophy Drugs by Segment - Percentage Breakdown of Value
Sales for Exon Skipping, Steroid Therapy, Mutation Suppression
and Other Segments for the Years 2023 & 2030
CANADA
Table 14: Canada Recent Past, Current & Future Analysis for
Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping,
Steroid Therapy, Mutation Suppression and Other Segments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 15: Canada 8-Year Perspective for Duchenne Muscular
Dystrophy Drugs by Segment - Percentage Breakdown of Value
Sales for Exon Skipping, Steroid Therapy, Mutation Suppression
and Other Segments for the Years 2023 & 2030
JAPAN
Duchenne Muscular Dystrophy Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
Table 16: Japan Recent Past, Current & Future Analysis for
Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping,
Steroid Therapy, Mutation Suppression and Other Segments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 17: Japan 8-Year Perspective for Duchenne Muscular
Dystrophy Drugs by Segment - Percentage Breakdown of Value
Sales for Exon Skipping, Steroid Therapy, Mutation Suppression
and Other Segments for the Years 2023 & 2030
CHINA
Duchenne Muscular Dystrophy Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in China for 2023 (E)
Table 18: China Recent Past, Current & Future Analysis for
Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping,
Steroid Therapy, Mutation Suppression and Other Segments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 19: China 8-Year Perspective for Duchenne Muscular
Dystrophy Drugs by Segment - Percentage Breakdown of Value
Sales for Exon Skipping, Steroid Therapy, Mutation Suppression
and Other Segments for the Years 2023 & 2030
EUROPE
Duchenne Muscular Dystrophy Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
Irish Boys with nonsense mutation Duchenne muscular dystrophy
(nmDMD) Gains Access to Key, Life-Supporting Drug
CHMP Rejects Exondys 51 in Europe
Table 20: Europe Recent Past, Current & Future Analysis for
Duchenne Muscular Dystrophy Drugs by Geographic Region -
France, Germany, Italy, UK and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR
Table 21: Europe 8-Year Perspective for Duchenne Muscular
Dystrophy Drugs by Geographic Region - Percentage Breakdown of
Value Sales for France, Germany, Italy, UK and Rest of Europe
Markets for Years 2023 & 2030
Table 22: Europe Recent Past, Current & Future Analysis for
Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping,
Steroid Therapy, Mutation Suppression and Other Segments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 23: Europe 8-Year Perspective for Duchenne Muscular
Dystrophy Drugs by Segment - Percentage Breakdown of Value
Sales for Exon Skipping, Steroid Therapy, Mutation Suppression
and Other Segments for the Years 2023 & 2030
FRANCE
Duchenne Muscular Dystrophy Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in France for 2023 (E)
Table 24: France Recent Past, Current & Future Analysis for
Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping,
Steroid Therapy, Mutation Suppression and Other Segments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 25: France 8-Year Perspective for Duchenne Muscular
Dystrophy Drugs by Segment - Percentage Breakdown of Value
Sales for Exon Skipping, Steroid Therapy, Mutation Suppression
and Other Segments for the Years 2023 & 2030
GERMANY
Duchenne Muscular Dystrophy Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
Table 26: Germany Recent Past, Current & Future Analysis for
Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping,
Steroid Therapy, Mutation Suppression and Other Segments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 27: Germany 8-Year Perspective for Duchenne Muscular
Dystrophy Drugs by Segment - Percentage Breakdown of Value
Sales for Exon Skipping, Steroid Therapy, Mutation Suppression
and Other Segments for the Years 2023 & 2030
ITALY
Table 28: Italy Recent Past, Current & Future Analysis for
Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping,
Steroid Therapy, Mutation Suppression and Other Segments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 29: Italy 8-Year Perspective for Duchenne Muscular
Dystrophy Drugs by Segment - Percentage Breakdown of Value
Sales for Exon Skipping, Steroid Therapy, Mutation Suppression
and Other Segments for the Years 2023 & 2030
UNITED KINGDOM
Duchenne Muscular Dystrophy Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in the United Kingdom
for 2023 (E)
Table 30: UK Recent Past, Current & Future Analysis for
Duchenne Muscular Dystrophy Drugs by Segment - Exon Skipping,
Steroid Therapy, Mutation Suppression and Other Segments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 31: UK 8-Year Perspective for Duchenne Muscular Dystrophy
Drugs by Segment - Percentage Breakdown of Value Sales for Exon
Skipping, Steroid Therapy, Mutation Suppression and Other
Segments for the Years 2023 & 2030
REST OF EUROPE
Table 32: Rest of Europe Recent Past, Current & Future Analysis
for Duchenne Muscular Dystrophy Drugs by Segment - Exon
Skipping, Steroid Therapy, Mutation Suppression and Other
Segments - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2022 through 2030 and % CAGR
Table 33: Rest of Europe 8-Year Perspective for Duchenne
Muscular Dystrophy Drugs by Segment - Percentage Breakdown of
Value Sales for Exon Skipping, Steroid Therapy, Mutation
Suppression and Other Segments for the Years 2023 & 2030
ASIA-PACIFIC
Duchenne Muscular Dystrophy Drugs Market Presence - Strong/
Active/Niche/Trivial - Key Competitors in Asia-Pacific for
2023 (E) 1
Table 34: Asia-Pacific Recent Past, Current & Future Analysis
for Duchenne Muscular Dystrophy Drugs by Segment - Exon
Skipping, Steroid Therapy, Mutation Suppression and Other
Segments - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2022 through 2030 and % CAGR
Table 35: Asia-Pacific 8-Year Perspective for Duchenne Muscular
Dystrophy Drugs by Segment - Percentage Breakdown of Value
Sales for Exon Skipping, Steroid Therapy, Mutation Suppression
and Other Segments for the Years 2023 & 2030
REST OF WORLD
Table 36: Rest of World Recent Past, Current & Future Analysis
for Duchenne Muscular Dystrophy Drugs by Segment - Exon
Skipping, Steroid Therapy, Mutation Suppression and Other
Segments - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2022 through 2030 and % CAGR
Table 37: Rest of World 8-Year Perspective for Duchenne
Muscular Dystrophy Drugs by Segment - Percentage Breakdown of
Value Sales for Exon Skipping, Steroid Therapy, Mutation
Suppression and Other Segments for the Years 2023 & 2030
IV. COMPETITION
Read the full report: https://www.reportlinker.com/p06040995/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
